PharmaCyte Biotech Declares Stable Test Outcome on Cells

PharmaCyte Biotech, Inc., a California based biotechnology company focused on the goal of developing advanced cellular therapies for treating cancer, and diabetes with the application of company’s signature live-cell encapsulation technology which has the market name of Cell-in-a-Box®, announced on Monday, July 12, that the wait has been rewarded.

Following three years of consecutive storage inside a vapor phase liquid nitrogen, the primary cytochrome P450 expressing cells obtained from PharmaCyte Master Cell Bank (MCB) which was manufactured by the Eurofins Lancaster Laboratories have successfully sustained, and maintained their viability along with excellent enzymatic activity, the two most critical characteristics considered while assessing the stability.Another distinctive study was conducted previously indicating positive test results of the CypCaps product when stored at -80⁰C analyzed across varying timepoints.

The enzymatic activity is considered to be crucial in identifying the cell performance, and effectiveness. It is typically a property that is capable of stimulating activation of low dose ifosfamide delivered to patients ultimately killing the cancerous tumors. Hence, good enzymatic activity is an equivalent measure of displaying the effectiveness of cells.

 It is of significant importance that the stability of MCB cells is displayed as they will be utilized as a resource for consistent, and ongoing production of future batches required for PharmaCyte clinical trial product known as CypCaps™. Owing to this, the United States Food and Drug Administration appealed for stability tests of the MCB cells. The company’s Chief Executive Officer, Kenneth L. Waggoner addressed the successful generation of data on cell viability.